Purmorphamine

Catalog No.S3042 Synonyms: Shh Signaling Antagonist VI

For research use only.

Purmorphamine (Shh Signaling Antagonist VI), which directly binds and activates Smoothened, blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM in HEK293T cell and also is an inducer of osteoblast differentiation with EC50 of 1 μM. Purmorphamine can reduce both basal and induced autophagy.

Purmorphamine Chemical Structure

CAS No. 483367-10-8

Selleck's Purmorphamine has been cited by 39 publications

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Other Hedgehog/Smoothened Products

Biological Activity

Description Purmorphamine (Shh Signaling Antagonist VI), which directly binds and activates Smoothened, blocks BODIPY-cyclopamine binding to Smo with IC50 of ~ 1.5 μM in HEK293T cell and also is an inducer of osteoblast differentiation with EC50 of 1 μM. Purmorphamine can reduce both basal and induced autophagy.
Targets
Smoothened [1]
(HEK293T cells)
~1.5 μM
In vitro

Purmorphamine activates the Hedgehog pathway by directly binds and activates Smoothened with IC50 of ~ 1.5 μM in compete with cyclopamine, a Smo antagonist. [1] Purmorphamine is a potent inducer of osteogenesis in multipotent C3H10T1/2 cells. The EC50 (based on ALP expression) for Purmorphamine is 1 μM in C3H10T1/2 cells. Purmorphamine (1 μM) and BMP-4 (100 ng/mL) together increase ALP activity more than 90-fold in 3T3-L1 cells. [2] In contrast to BMP-4, Purmorphamine induces osteogenesis by activating Hedgehog signaling in multipotent mesenchymal progenitor cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C3H10T1/2 NWP4e5FFTnWwY4Tpc44h[XO|YYm= MkmwOkBl[Xm| NE\TcFJC[3Srdnn0fUBifCCVbX:gbY4hdW:3c3WgR|NJOTCWMT:yJINmdGy|IHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iClZXzsJIRq\m[ncnXueIlifGmxbjDpcpRwKG:|dHXvZoxie3RiaX7jeYJifGWmIH\vdkA3KGSjeYOgZpkh[WytYXzpcoUheGixc4DoZZRie2ViYYPzZZktKEWFNUCgQUAxNjhizszNMi=> MlzKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd2MkmyOVUoRjJ5NEK5NlU2RC:jPh?=
Shh Light2 M4Ty[mZ2dmO2aX;uJIF{e2G7 MlzZN|AhcHK| Mn7TRYN1cX[jdHnvckBw\iCVaHigbY4hdW:3c3WgV4hpKEyrZ3j0NkBk\WyuczDh[pRmeiB|MDDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyIE2gNUDPxE1w Ml;1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2MEiwPFgoRjF4NEC4NFg5RC:jPh?=
C3H10T1/2 M2nIPGZ2dmO2aX;uJIF{e2G7 M3PPPGlv\HWldHnvckBw\iCxc4Tlc4dmdmW|aYOgbY4hdW:3c3WgR|NJOTCWMT:yJINmdGy|IHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCxc4Tlc4Jt[XO2IIPw[YNq\mmlIH3hdotmeiCjbHvhcIlv\SCyaH;zdIhifGG|ZTDifUBqdW23bn;mcJVwemW|Y3XuZ4UhdWW2aH;kMEBGSzVyIE2gNUDPxE1w NYP1[HptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0NFgxODNpPkG2OFA5ODB|PD;hQi=>
HEK293T NHfDOoFHfW6ldHnvckBie3OjeR?= M1Pve|EhcHJ? MVXJcohq[mm2aX;uJI9nKEKRRFnQXU1kgWOub4DhcYlv\SCkaX7kbY5oKHSxIGPtc{BmgHC{ZYPz[YQhcW5iSFXLNlk{XCClZXzsd{Bi\nSncjCxJIhzKGK7IH\seY9z\XOlZX7j[UBucWO{b4Pjc5B6NCCLQ{WwJF0hOS53IN88UU4> M3T1clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NEC4NFg5Lz5zNkSwPFA5QDxxYU6=
Shh Light2 NHLJU2lHfW6ldHnvckBie3OjeR?= MoK4N|AhcHK| MnnHRYN1cX[jdHnvckBw\iCVaHigbY4hdW:3c3WgV4hpKEyrZ3j0NkBk\WyuczDhd5Nme3OnZDDhd{Bj\XSjLXfhcIFkfG:|aXThd4Uh[WO2aY\peJkh[W[2ZYKgN|AhcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSCrbjDwdoV{\W6lZTDv[kAyODBibl2gN{1s\XSxLV6tZY1qdm:ndHj5cE1PLy2jbXnuc4NieHKxeXzkbYh6\HKxY3nucoFud3muIHP5Z4xweGGvaX7l M2PCelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NEC4NFg5Lz5zNkSwPFA5QDxxYU6=
HEK293T M3PtUmZ2dmO2aX;uJIF{e2G7 NFjDcIk2KHWP M2TlPFQhcHK| NHfzW29KdmirYnn0bY9vKG:oIFLPSGlRYS2leXPsc5BidWmwZTDibY5lcW6pIITvJHNudyCQLYTldo1qdmGuIHP5d5RmcW6nIHTvcYFqdiCneIDy[ZN{\WRiaX6gTGVMOjl|VDDj[YxteyCjdDC1JJVOKGGodHXyJFQhcHK|IHL5JIZtfW:{ZYPj[Y5k\SCvaXPyc5Nkd3C7 NGnVSmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkSwPFA5QCd-MU[0NFgxQDh:L3G+
HEK293T MWHGeY5kfGmxbjDhd5NigQ>? NWPkWFN5PSC3TR?= NYDzRWt[PCCqcoO= NGLTd3VKdmirYnn0bY9vKG:oIFLPSGlRYS2leXPsc5BidWmwZTDibY5lcW6pIITvJHNudyCFLYTldo1qdmGuIHP5eI9xdGG|bXnjJIRwdWGrbjDlfJBz\XO|ZXSgbY4hUEWNMkmzWEBk\WyuczDheEA2KHWPIHHmeIVzKDRiaILzJIJ6KG[udX;y[ZNk\W6lZTDtbYNzd3Olb4D5 NEXOVYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkSwPFA5QCd-MU[0NFgxQDh:L3G+
SK-N-MC NF3peXZyUFSVIHHzd4F6 M125UpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz NGL0[mM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Assay
Methods Test Index PMID
Western blot Patch1 / Gli1 / LC3 / p62 26609469
Immunofluorescence SOX18 26588701
Growth inhibition assay Cell viability 26588701
In vivo Purmorphamine up-regulates ALP expression in human mesenchymal stem cell-based constructs on rats. [4]

Protocol (from reference)

Kinase Assay:[1]
  • Binding assay:

    Smo binding assays are conducted with BODIPY-cyclopamine and Smo-overexpressing cells as previously described4,5, using CMV promoter-based, SV40 origin-containing expression constructs for Smo-Myc3, the deletion mutant SmoCRD (deletion of amino acids 68 to 182), and SmoCT (deletion of amino acids 556 to 793). HEK 293T cells are grown on poly-D-lysine-treated glass coverslips in 12-well plates until 70% confluency and then transfected with the appropriate expression construct (0.5 g/well) using FuGene 6 according the manufacturer's protocols. Two days after transfection, the HEK 293T cells are incubated with DMEM containing 0.5% bovine calf serum, 5 nM BODIPY-cyclopamine, and varying concentrations of Purmorphamine (0, 1.5, or 5 M) (1 mL/well) for 1 h at 37 ℃. The Smo-overexpressing cells are then washed with 1 × PBS buffer (1 mL/well), mounted with DAPI-containing medium, and visualized using a Leica DM4500B fluorescence microscope. For binding assays using fixed cells, the Smo-overexpressing HEK 293T cells are fixed with 3% paraformaldehyde in 1 × PBS buffer for 10 min at room temperature (1 mL/well), treated with 1 × PBS containing 10 mM glycine and 0.2% sodium azide for 5 min (1 mL/well), washed with 1 × PBS buffer (1 mL/well), and treated with the Purmorphamine-containing media described above for 4 h at room temperature.

Cell Research:[2]
  • Cell lines: C3H10T1/2 cell
  • Concentrations: 0.5-10 μM
  • Incubation Time: 4 days
  • Method: C3H10T1/2 cells are expanded in T175 flasks; cells at 13th passage are detached by trypsin/EDTA and diluted in the growth media. The resulting cell suspension is then plated into black clear bottom 384-well plates with 2500 cells/well in 100 µL growth medium using a Multi-dropTM liquid delivery system. After overnight incubation, cells attached to the bottom of the wells. A stock solution of each Purmorphamine in DMSO (500 nL) is delivered into corresponding well using a Mini TrakTM multiposition dispenser system to make a final concentration of 5μM of Purmorphamine. Cells are then incubated at 37 ℃ with 5% CO2 in air atmosphere. After 4 days, the medium is removed and 10 μL of passive lysis buffer is added into each well. After 5 min, 10 μL of alkaline phosphatase substrate solution is added to each well. After incubating 15 min at room temperature, the plates are read on an Acquest high-throughput plate reader following the manufacturer's protocol.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.

1mg/mL

Chemical Information

Molecular Weight 520.62
Formula

C31H32N6O2

CAS No. 483367-10-8
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1CCC(CC1)N2C=NC3=C(N=C(N=C32)OC4=CC=CC5=CC=CC=C54)NC6=CC=C(C=C6)N7CCOCC7

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Purmorphamine | Purmorphamine supplier | purchase Purmorphamine | Purmorphamine cost | Purmorphamine manufacturer | order Purmorphamine | Purmorphamine distributor